Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | FBP1 | P09467 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264463 | 1.00 | G6PD (0.38) | G6PDPOLBGAATDP1LMNA | |
| SCHEMBL14575602 | 0.86 | G6PD (0.41) | G6PDPOLBGAATDP1ALDH1A1 | |
| SCHEMBL14575603 | 0.86 | G6PD (0.41) | G6PDPOLBGAATDP1ALDH1A1 | |
| SCHEMBL3454524 | 0.80 | MEN1 (0.39) | GAAALDH1A1KMT2AMAPT | |
| SCHEMBL1404270 | 0.79 | G6PD (0.42) | G6PDPOLBGAATDP1ALDH1A1 | |
| SCHEMBL4712634 | 0.79 | G6PD (0.41) | G6PDPOLBGAATDP1ALDH1A1 | |
| SCHEMBL10696828 | 0.79 | FBP1 (0.44) | LMNAALDH1A1FBP1TSHREGFR | |
| SCHEMBL9065978 | 0.76 | AKR1C3 (0.47) | TDP1LMNAALDH1A1FBP1KMT2A | |
| SCHEMBL14617615 | 0.74 | G6PD (0.45) | G6PDPOLBGAATDP1ALDH1A1 | |
| SCHEMBL27374051 | 0.74 | G6PD (0.39) | G6PDPOLBGAATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340972-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | Oklahoma Medical Research Foundation (US) | 2018-07-04 | — | — | EP | claimed |
| WO-2017048778-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2017-03-23 | — | — | WO | claimed |
| CN-105796602-A | Treatment of stroke using isolated placental cells | 人类起源公司 | 2016-07-27 | — | — | CN | claimed |
| EP-2574328-A2 | Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair | The Procter and Gamble Company (US) | 2013-04-03 | — | — | EP | claimed |
| US-20120258185-A1 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | OBLONG JOHN ERICH (US) | 2012-10-11 | — | — | US | claimed |
| CN-102186971-A | Treatment of stroke using isolated placental cells | ANTHROGENESIS CORP | 2011-09-14 | — | — | CN | claimed |
| US-20110071117-A1 | COMBINATIONS OF ANTIOXIDANTS AND ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2011-03-24 | — | — | US | claimed |
| WO-2009140457-A2 | COMBINATIONS OF ANTIOXIDANTS AND ANTI-INFLAMMATORY DRUGS IN THE OF TREATMENT INFLAMMATORY BOWEL DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2009-11-19 | — | — | WO | claimed |
| CN-101511331-A | Hair care compositions that can make hair appear thicker and fuller | PROCTER & GAMBLE (US) | 2009-08-19 | — | — | CN | claimed |
| EP-2056783-A2 | HAIR CARE COMPOSITIONS THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | The Procter and Gamble Company (US) | 2009-05-13 | — | — | EP | claimed |
| US-RE35112-E | Administering phenyl butyl nitrone or derivative in carrier in dosage to prevent or reverse oxidative central nervous system tissue damage | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-12-05 | — | — | US | claimed |
| EP-0496796-B1 | METHOD AND COMPOSITIONS FOR INHIBITION OF DISORDERS ASSOCIATED WITH OXIDATIVE DAMAGE | OKLAHOMA MED RES FOUND (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0518951-A4 | PHENYL BUTYL NITRONE COMPOSITIONS FOR PREVENTION OF GASTRIC ULCERATION | — | 1993-02-24 | — | — | EP | claimed |
| EP-0518951-A1 | PHENYL BUTYL NITRONE COMPOSITIONS FOR PREVENTION OF GASTRIC ULCERATION | Oklahoma Medical Research Foundation (US) | 1992-12-23 | — | — | EP | claimed |
| EP-0496796-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF DISORDERS ASSOCIATED WITH OXIDATIVE DAMAGE. | OKLAHOMA MED RES FOUND (US) | 1992-08-05 | — | — | EP | claimed |
| WO-1991013618-A1 | PHENYL BUTYL NITRONE COMPOSITIONS FOR PREVENTION OF GASTRIC ULCERATION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-09-19 | — | — | WO | claimed |
| US-5036097-A | Antiinflammatory agents/non-steriodal | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-07-30 | — | — | US | claimed |
| US-5025032-A | For ischemia or inflammation of brain or nervous system | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-06-18 | — | — | US | claimed |
| US-5017458-A | Oxidation resistance | HITACHI, LTD. (JP) | 1991-05-21 | — | — | US | claimed |
| WO-1991005552-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF DISORDERS ASSOCIATED WITH OXIDATIVE DAMAGE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-05-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258185-A1 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | SHH, FSCN1, CUTA | G6PD 3025/4885POLB 3443/4885GAA 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.